Publications and communications of Jerusalem, Guy

Grégoire, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., JERUSALEM, G., Willems, S., & Bragard, I. (In press). Randomized-controlled trial of an intervention combining self-care and self-hypnosis on fatigue, sleep and emotional distress in post-treatment cancer patients: 1-year follow up. International Journal of Clinical and Experimental Hypnosis. doi:10.1080/00207144.2022.2049973

Grégoire, C., Marie, N., Sombrun, C., FAYMONVILLE, M.-E., Kotsou, I., Van Nitsen, V., De Ribaucourt, S., JERUSALEM, G., LAUREYS, S., VANHAUDENHUYSE, A.* , & Gosseries, O.*. (2022). Hypnosis, meditation and self-induced cognitive trance to improve post-treatment oncological patients’ quality of life: study protocol. Frontiers in Psychology. doi:10.3389/fpsyg.2022.807741

ONESTI, C. E., Schroeder, H., Rorive, A., Sautois, B., Lecocq, M., Goffin, M., Gonne, E., Collinge, A., Nicolaers, L., Wéra, O., Catot, A., Loly, C., Paulus, A., Sibille, A., Lousberg, L., Troisfontaine, F., Collignon, J., Gennigens, C., Frères, P., & Jerusalem, G. (2021). Oncological patients' reactions to COVID-19 pandemic: A single institution prospective study. Cancer Reports, 1571. doi:10.1002/cnr2.1571

Poncin, A., Onesti, C. E., JOSSE, C., Boulet, D., Thiry, J., Bours, V., & Jerusalem, G. (August 2021). Immunity and Breast Cancer: Focus on Eosinophils. Biomedicines, 9 (9), 1087. doi:10.3390/biomedicines9091087

Grégoire, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., JERUSALEM, G., Willems, S., & Bragard, I. (07 July 2021). Effets d’une intervention basée sur l’hypnose sur la fatigue, le sommeil et la détresse de patients oncologiques. Paper presented at 11ème Congrès de l’Association Francophone de Psychologie de la Santé.

Uyisenga, J. P.* , Debit, A.* , Poulet, C., Frères, P., Poncin, A., Thiry, J., Mutesa, L., Jerusalem, G., Bours, V.* , & JOSSE, C.*. (03 June 2021). Differences in plasma microRNA content impair microRNA-based signature for breast cancer diagnosis in cohorts recruited from heterogeneous environmental sites. Scientific Reports, 11 (1), 11698. doi:10.1038/s41598-021-91278-0

Piccart, M., Procter, M., Fumagalli, D., de Azambuja, E., Clark, E., Ewer, M. S., Restuccia, E., Jerusalem, G., Dent, S., Reaby, L., Bonnefoi, H., Krop, I., Liu, T.-W., Pieńkowski, T., Toi, M., Wilcken, N., Andersson, M., Im, Y.-H., Tseng, L. M., & Thomssen, C. (29 April 2021). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39 (13), 1448-1457. doi:10.1200/JCO.20.01204

GREGOIRE, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., JERUSALEM, G., Willems, S., & Bragard, I. (February 2021). Randomized-controlled trial of a group intervention combining self-hypnosis and self-care: secondary results on self-esteem, emotional distress and regulation, and mindfulness in post-treatment cancer patients. Quality of Life Research, 30, 425-436. doi:10.1007/s11136-020-02655-7

GENNIGENS, C., DE CUYPERE, M., HERMESSE, J., KRIDELKA, F., & JERUSALEM, G. (2021). Optimal treatment in locally advanced cervical cancer. Expert Review of Anticancer Therapy, 657-671. doi:10.1080/14737140.2021.1879646

Onesti, C. E., & Jerusalem, G. (2021). CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Review of Anticancer Therapy, 21 (3), 283-298. doi:10.1080/14737140.2021.1852934

ONESTI, C. E., Tagliamento, M., Curigliano, G., Harbeck, N., Bartsch, R., Wildiers, H., Tjan-Heijnen, V., Martin, M., Rottey, S., Generali, D., Campone, M., Cristofanilli, M., Pusztai, L., Peeters, M., Berchem, G., Cortes, J., Ruhstaller, T., Ciruelos, E., Rugo, H. S., & Jerusalem, G. (2021). Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. JCO global oncology, 7, 162-172. doi:10.1200/GO.20.00589

SCHEEN, A., BEGUIN, Y., & JERUSALEM, G. (2021). L’oncologie, à un tournant de son histoire. Revue Médicale de Liège, 76, 297-299.

Schettini, F., Giuliano, M., Giudici, F., Conte, B., De Placido, P., Venturini, S., Rognoni, C., Di Leo, A., Locci, M., Jerusalem, G., Del Mastro, L., Puglisi, F., Conte, P., De Laurentiis, M., Pusztai, L., Rinmawi, M. F., Schiff, R., Arpino, G., De Placido, S., & Generali, D. (2021). Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers, 13 (6), 1458 (21. doi:10.3390/cancers13061458

Onesti, C. E., JOSSE, C., Boulet, D., Bours, V., & JERUSALEM, G. (2020). High plasmatic levels of IL-4 and IL- 13 are associated with recurrence and worse survival in breast cancer. Tumori Journal.

ONESTI, C. E., JOSSE, C., Beaumecker, B., Boulet, D., Thiry, J., BOURS, V., & JERUSALEM, G. (2020). The relative eosinophil count in breast cancer as an emerging prognostic biomarker. European Journal of Cancer. doi:10.1016/S0959-8049(20)30766-8

JERUSALEM, G., ONESTI, C. E., Generali, D., Harbeck, N., Wildiers, H., Curigliano, G., Campone, M., Tjan-Heijnen, V., Martin, M., Cristofanilli, M., Pusztai, L., Bartsch, R., Peeters, M., Berchem, G., Tagliamento, M., Cortès, J., Ruhsthaller, T., Ciruelos, E., Rottey, S., & Rugo, H. (2020). Expected medium and long term impact of the COVID-19 outbreak in oncology. Annals of Oncology.

ONESTI, C. E., Rugo, H. S., Generali, D., Peeters, M., Zaman, K., Wildiers, H., Harbeck, N., Martin, M., Cristofanilli, M., Cortes, J., Tjan-Heijnen, V., Hurvitz, S. A., Berchem, G., Tagliamento, M., Campone, M., Bartsch, R., De Placido, S., Puglisi, F., Rottey, S., & JERUSALEM, G. (August 2020). Oncological care organisation during COVID-19 outbreak. ESMO Open, 5. doi:10.1136/esmoopen-2020-000853

POTTIER, C., Fresnais, M., Gilon, M., JERUSALEM, G., Longuespée, R.* , & Sounni, N. E.*. (2020). Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers. doi:10.3390/cancers12030731

Corona, S. P., Giudici, F., JERUSALEM, G., Ciruelos, E., Strina, C., Sirico, M., Bernocchi, O., Milani, M., Dester, M., Ziglioli, N., Barbieri, G., Cervoni, V., Montemurro, F., & Generali, D. (2020). Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus : a retrospective exploratory analysis of the BALLET study. Oncotarget, 11 (23), 2172-2181. doi:10.18632/oncotarget.27612

ONESTI, C. E., JOSSE, C., Boulet, D., Thiry, J., Beaumecker, B., BOURS, V., & JERUSALEM, G. (2020). Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse. Oncoimmunology. doi:10.1080/2162402X.2020.1761176

Ribi, K., Luo, W., Colleoni, M., Karlsson, P., Chirgwin, J., Aebi, S., Jerusalem, G., Neven, P., Di Lauro, V., Gomez, H. L., Ruhstaller, T., Abdi, E., Biganzoli, L., Müller, B., Barbeaux, A., Graas, M.-P., Rabaglio, M., Francis, P. A., Foukakis, T., & Bernhard, J. (2020). Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. British Journal of Cancer, 122 (7), 1119. doi:10.1038/s41416-019-0709-x

Schroyen, S., Letenneur, L., Missotten, P., Jerusalem, G., & Adam, S. (2020). Impact of self-perception of aging on mortality of older patients in oncology. Cancer Medicine, 9, 2283-2289. doi:10.1002/cam4.2819

Grégoire, C., FAYMONVILLE, M.-E., VANHAUDENHUYSE, A., Charland-Verville, V., JERUSALEM, G., Dardenne, N., & Bragard, I. (September 2019). Effects of a hypnosis-based intervention on fatigue and sleep difficulties in post-treatment cancer patients. Journal of Psychosocial Oncology Research and Practice, 1 (1S).

Bicego, A. Y., Grégoire, C., Cassol, H., FAYMONVILLE, M.-E., Nyssen, A.-S., Rousseaux, F., JERUSALEM, G., Laureys, S., Bragard, I., & VANHAUDENHUYSE, A. (30 May 2019). Study of the impact of non-pharmacological techniques (self-hypnosis/self-care) on cognitive complaints in cancer patients. Paper presented at Hypnosis New Generation, Budapest, Hungary.

Bicego, A. Y., Grégoire, C., Cassol, H., FAYMONVILLE, M.-E., Nyssen, A.-S., Rousseaux, F., JERUSALEM, G., LAUREYS, S., Bragard, I., & VANHAUDENHUYSE, A. (14 May 2019). Learning self-hypnosis/self-care improves cognitive complaints in cancer patients. Poster session presented at Annual Meeting of the Belgian Association for Psychological Sciences, Liège, Belgium.

ONESTI, C. E., BOEMER, F., JOSSE, C., LEDUC, S., Poulet, C., BOURS, V., & JERUSALEM, G. (2019). Tryptophan catabolism differentiates breast cancer patients from healthy controls but does not predict outcome. Annals of Oncology.

Debit, A., Poulet, C., JOSSE, C., Azencott, C.-A., Jerusalem, G., Van Steen, K., & BOURS, V. (15 March 2019). TOWARDS AN ACCURATE CANCER DIAGNOSIS MODELIZATION:COMPARISON OF RANDOM FOREST STRATEGIES. Poster session presented at 19th BeSHG meeting 15th March 2019 Liege, Belgium, Liege, Belgium.

Latge, G., Poulet, C., JOSSE, C., JERUSALEM, G., & Bours, V. (15 March 2019). Role of DNA methylation in INK4a-ARF-INK4b locus expression in breast cancer. Poster session presented at 19th Meeting of the Belgian Society of Human Genetics, Liège, Belgium.

Lancellotti, P., Suter, T. M., Lopez-Fernandez, T., Galderisi, M., Lyon, A. R., Van der Meer, P., Cohen Solal, A., Zamorano, J.-L., Jerusalem, G., Moonen, M., Aboyans, V., Bax, J. J., & Asteggiano, R. (2019). Cardio-Oncology Services: rationale, organization, and implementation: A report from the ESC Cardio-Oncology council. European Heart Journal. doi:10.1093/eurheartj/ehy453

ONESTI, C. E., BOEMER, F., JOSSE, C., LEDUC, S., BOURS, V., & JERUSALEM, G. (2019). Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy. Journal of Translational Medicine, 17, 239. doi:10.1186/s12967-019-1984-2

ONESTI, C. E., FRERES, P., & JERUSALEM, G. (2019). Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment. Journal of Thoracic Disease. doi:10.21037/jtd.2018.12.47

Grégoire, C., Faymonville, M.-E., VANHAUDENHUYSE, A., Charland-Verville, V., Jerusalem, G., & Bragard, I. (15 November 2018). Randomized controlled trial of an 8-week intervention combining self-care and hypnosis for post-treatment cancer patients: study protocol. BMC Cancer, 18 (1113). doi:10.1186/s12885-018-5046-6

ONESTI, C. E., JOSSE, C., Poncin, A., FRERES, P., Poulet, C., BOURS, V., & JERUSALEM, G. (2018). Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment. Oncotarget. doi:10.18632/oncotarget.26120

Debit, A., JOSSE, C., JERUSALEM, G., BOURS, V., & Poulet, C. (13 September 2018). Towards an accurate cancer diagnosis modelization:Comparison of Random Forest strategies. Poster session presented at JOINT MEETING GIGA-CANCER DAY 2018 / EDT-CANCEROLOGY, Liege, Belgium.

ONESTI, C. E., JOSSE, C., PONCIN, A., FRERES, P., Poulet, C., BOURS, V., & JERUSALEM, G. (13 September 2018). Predictive and prognostic role of peripheral blood eosinophil count in triple negative and hormone receptor negative/HER2 positive breast cancers patients undergoing neoadjuvant treatment. Paper presented at GIGA-Cancer Day 2018 / EDT-Cancerology Vascular landscape and (pre)metastatic niche in cancer biology.

Freres, P., Bouznad, N., Servais, L., JOSSE, C., Wenric, S., Poncin, A., Thiry, J., Moonen, M., Oury, C., Lancellotti, P., Bours, V., & Jerusalem, G. (2018). Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer, 18 (1). doi:10.1186/s12885-018-4015-4

Latge, G., Poulet, C., Bours, V., JOSSE, C., & Jerusalem, G. (2018). Natural Antisense Transcripts: Molecular Mechanisms and Implications in Breast Cancers. International Journal of Molecular Sciences, 19 (1). doi:10.3390/ijms19010123

Grégoire, C., FAYMONVILLE, M.-E., JERUSALEM, G., Bragard, I., Charland-Verville, V., & VANHAUDENHUYSE, A. (November 2017). Intérêt et utilisation de l’hypnose pour améliorer le bien-être physique et psychologique en oncologie. HEGEL: Penser par Soi-Même, 7 (4), 267-275. doi:10.4267/2042/63778

FRERES, P., GENNIGENS, C., Martin, D., & Jerusalem, G. (October 2017). Leptomeningeal carcinomatosis from solid tumours : a systematic review of the literature. Belgian Journal of Medical Oncology, 11, 259-264.

Grégoire, C., Bragard, I., VANHAUDENHUYSE, A., Charland-Verville, V., Etienne, A.-M., JERUSALEM, G., & FAYMONVILLE, M.-E. (19 May 2017). Effets d'une intervention basée sur l'hypnose sur la fatigue et la détresse de patients atteints d'un cancer : une étude contrôlée randomisée. Poster session presented at Congrès de la faculté de Psychologie, Logopédie et Sciences de l’Education de l’Université de Liège.

Grégoire, C., FAYMONVILLE, M.-E., JERUSALEM, G., Etienne, A.-M., COUCKE, P., Dupuis, G., Lanctôt, D., & Bragard, I. (19 May 2017). Etude des effets à long terme de différentes interventions de groupe pour améliorer la détresse émotionnelle et la fatigue chez des patientes atteintes d’un cancer du sein. Poster session presented at Congrès de la faculté de Psychologie, Logopédie et Sciences de l’Education de l’Université de Liège.

Wenric, S., El Guendi, S., CABERG, J.-H., Bezzaou, W., Fasquelle, C., Charloteaux, B., Karim, L., Hennuy, B., FRERES, P., COLLIGNON, J., BOUKERROUCHA, M., SCHROEDER, H., Olivier, F., Jossa, V., JERUSALEM, G., JOSSE, C., & BOURS, V. (May 2017). Transcriptome wide analysis of natural antisense transcripts shows potential role in breast cancer. Poster session presented at 50th meeting of the European Society of Human Genetics, Copenhagen, Denmark.

Lancellotti, P., Galderisi, M., Donal, E., Edvardsen, T., Popescu, B. A., Farmakis, D., Filippatos, G., Habib, G., Lestuzzi, C., Santoro, C., MOONEN, M., Jerusalem, G., Andarala, M., & Anker, S. D. (2017). Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. ESC Heart Failure, 4 (3), 312-318. doi:10.1002/ehf2.12162

Wenric, S., ElGuendi, S., CABERG, J.-H., Bezzaou, W., Fasquelle, C., Charloteaux, B., Karim, L., Hennuy, B., FRERES, P., COLLIGNON, J., BOUKERROUCHA, M., SCHROEDER, H., OLIVIER, F., Jossa, V., Jerusalem, G., JOSSE, C., & Bours, V. (2017). Transcriptome-wide analysis of natural antisense transcripts shows their potential role in breast cancer. Scientific Reports, 7 (1), 17452. doi:10.1038/s41598-017-17811-2

Yip, C., Foidart, P., Somja, J., Truong, A., Lienard, M., Feyereisen, E., SCHROEDER, H., GOFFLOT, S., Donneau, A.-F., COLLIGNON, J., Delvenne, P., Sounni, N. E., Jerusalem, G., & Noël, A. (2017). MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib. British Journal of Cancer. doi:10.1038/bjc.2017.23

Schroyen, S., Adam, S., Marquet, M., Jerusalem, G., Thiel, S., Giraudet, A.-L., & Missotten, P. (11 March 2016). Ageism and communication in oncology. Poster session presented at Official 10th European Breast Cancer Conference (EBCC-10).

Baitar, A., Kenis, C., Moor, R., Decoster, L., Luce, S., Bron, D., Van Rijswijk, R., Rasschaert, M., Langenaeken, C., Jerusalem, G., Lobelle, J.-P., Flamaing, J., Milisen, K., & Wildiers, H. (2016). Corrigendum to "Implementation of geriatric assessment-based recommendations in older patients with cancer: A multicenter prospective study" [J. Geriatr. Oncol. 6 (2015) 401-410]. Journal of Geriatric Oncology, 7 (2), 142-3. doi:10.1016/j.jgo.2016.01.005

Bourcy, M., Suarez-Carmona, M., Lambert, J., Francart, M.-E., SCHROEDER, H., Delierneux, C., Skrypek, N., Thompson, E. W., JERUSALEM, G., Berx, G., Thiry, M., Blacher, S., Hollier, B. G., Noël, A., Oury, C., Polette, M., & Gilles, C. (2016). Tissue factor induced by epithelial-mesenchymal transition triggers a pro-coagulant state that drives metastasis of circulating tumor cells. Cancer Research, 76 (14), 4270-4282.

COLLIGNON, J., LOUSBERG, L., SCHROEDER, H., & JERUSALEM, G. (2016). Triple-negative breast cancer : treatment challenges and solutions. Breast Cancer, 8, 93-107. doi:10.2147/BCTT.S69488

FRERES, P., PONCIN, A., MOONEN, M., Josse, C., Oury, C., BOURS, V., LANCELLOTTI, P., & JERUSALEM, G. (2016). La cardiotoxicité des traitements anti-cancéreux. Revue Médicale de Liège, 71 (9), 382-387.

GONNE, E., COLLIGNON, J., JERUSALEM, G., & GENNIGENS, C. (2016). Le carcinome de site primitif inconnu, une entité pas si rare. Revue Médicale de Liège, 71 (10), 449-454.

LOUSBERG, L., COLLIGNON, J., & Jerusalem, G. (2016). Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Therapeutic Advances in Medical Oncology, 8 (6), 429-449. doi:10.1177/1758834016665077

Lousberg, L., & Jerusalem, G. (2016). Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer. Breast Cancer: Basic and Clinical Research, 10, 239-252. doi:10.4137/BCBCR.S12443

Schroyen, S., Missotten, P., Jerusalem, G., GILLES, C., & Adam, S. (2016). Ageism among nurses in oncology. International Psychogeriatrics. doi:10.1017/S1041610215001970

Freres, P.* , Wenric, S.* , BOUKERROUCHA, M., Fasquelle, C., Thiry, J., Bovy, N., Struman, I., Geurts, P., COLLIGNON, J., SCHROEDER, H., KRIDELKA, F., LIFRANGE, E., Jossa, V., Bours, V.* , Josse, C.* , & JERUSALEM, G.*. (2015). Circulating microRNA-based screening tool for breast cancer. Oncotarget. doi:10.18632/oncotarget.6786

Boukerroucha, M., Josse, C., SEGERS, K., El Guendi, S., FRERES, P., JERUSALEM, G., & Bours, V. (26 March 2015). BRCA1 germline mutation and glioblastoma development: report of cases. BMC Cancer, 15, 181. doi:10.1186/s12885-015-1205-1

Perez Palacios, A., Blomme, A., Boutry, S., Doumont, G., Sherer, F., Van Simaeys, G., Debois, D., JERUSALEM, G., COLLIGNON, J., DELVENNE, P., DETRY, O., De Pauw, E., Muller, R., Goldman, S., Castronovo, V., & Turtoi, A. (March 2015). Metabolomic, proteomic and preclinical imaging of patient-derived tumor xenografts for improving treatment of liver metastases patients. Acta Gastro-Enterologica Belgica, 78 (1), 134.

JERUSALEM, G. (29 January 2015). Do we have to change our anti-cancer strategy in case of cardiac toxicity ? Point of view of the oncologist. Paper presented at 34th Annual Congress Belgian Society of Cardiology, Brussels, Belgium.

Boukerroucha, M., Josse, C., El Guendi, S., Boujemla, B., Freres, P., Marée, R., Wenric, S., SEGERS, K., COLLIGNON, J., Jerusalem, G., & Bours, V. (2015). Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers. BMC Cancer, 15 (1), 755. doi:10.1186/s12885-015-1740-9

Bovy, N., Blomme, B., Freres, P., Dederen, S., Nivelles, O., Lion, M., Carnet, O., Martial, J., Noël, A., Thiry, M., Jerusalem, G., Josse, C., Bours, V., Tabruyn, S., & Struman, I. (2015). Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget. doi:10.18632/oncotarget.3520

Carnet, O.* , Lecomte, J.* , Masset, A., Primac, I., Durré, T., Maertens, L., Detry, B., Blacher, S., Gilles, C., Péqueux, C., Paupert, J., Foidart, J.-M., Jerusalem, G., Cataldo, D., & Noël, A. (2015). Mesenchymal stem cells shed amphiregulin at the surface of lung carcinoma cells in a juxtacrine manner. Neoplasia, 17 (7), 552-63. doi:10.1016/j.neo.2015.07.002

COLIN, P.-E., SCHROEDER, H., GONNE, E., Hanocq, F., ANDRE, C., RORIVE, A., Jerusalem, G., & COLLIGNON, J. (2015). BIOPSIE DES LESIONS SUSPECTES CHEZ LES PATIENTS AYANT PRESENTE UN CANCER DU SEIN. Revue Médicale de Liège, 70 (11), 563-8.

FRERES, P., GONNE, E., COLLIGNON, J., GIOT, J.-B., GENNIGENS, C., & JERUSALEM, G. (2015). Prise en charge de la neutropénie fébrile chez le patient cancéreux. Revue Médicale de Liège, 70 (4), 195-200.

JERUSALEM, G., COLLIGNON, J., Josse, C., SCHROEDER, H., RORIVE, A., FRERES, P., LAMBERT, F., KOOPMANSCH, B., PONCIN, A., & BOURS, V. (2015). Cancer du sein : de la thérapie ciblée à la médecine personnalisée. Revue Médicale de Liège, 70 (5-6), 269-276.

JERUSALEM, G., MOONEN, M., FRERES, P., & LANCELLOTTI, P. (2015). The European Association of Cardiovascular Imaging/Heart Faiture Association Cardiac Oncology Toxicity Registry : long-term benefits for breast cancer treatment. Future Oncology, 11 (20), 2791-2794. doi:10.2217/fon.15.227

Jerusalem, G., Neven, P., Marinsek, N., Zhang, J., Degun, R., Benelli, G., Saletan, S., Ricci, J.-F., & Andre, F. (2015). Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe. BMC Cancer, 15, 787. doi:10.1186/s12885-015-1762-3

Lancellotti, P., Anker, S. D., Donal, E., Edvardsen, T., Popescu, B. A., Farmakis, D., Filippatos, G., Habib, G., Maggioni, A. P., Jerusalem, G., & Galderisi, M. (2015). EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)-EURObservational Research Program of the European Society of Cardiology. European Heart Journal - Cardiovascular Imaging. doi:10.1093/ehjci/jev024

Maris, P., Blomme, A., Palacios, A. P., Costanza, B., Bellahcene, A., BIANCHI, E., GOFFLOT, S., Drion, P., Trombino, G. E., Di Valentin, E., CUSUMANO, G., MAWEJA, S., JERUSALEM, G., Delvenne, P., LIFRANGE, E., Castronovo, V., & Turtoi, A. (2015). Asporin Is a Fibroblast-Derived TGF-beta1 Inhibitor and a Tumor Suppressor Associated with Good Prognosis in Breast Cancer. PLoS Medicine, 12 (9), 1001871. doi:10.1371/journal.pmed.1001871

SCHROEDER, H., Hanocq, F., COLLIGNON, J., Colin, P.-E., Depuis, Z., Triffaux, F., RORIVE, A., & JERUSALEM, G. (2015). Cancer du sein: intérêt du bilan d’extension par imagerie lors du diagnostic initial et du suivi les trois premières années après le diagnostic. Revue Médicale de Liège, 70 (3), 140-147.

Schroyen, S., Adam, S., JERUSALEM, G., & Missotten, P. (2015). Ageism and its clinical impact in oncogeriatry: state of knowledge and therapeutic leads. Clinical Interventions in Aging, 10, 117-125. doi:10.2147/CIA.S70942

Schroyen, S., Adam, S., JERUSALEM, G., & Missotten, P. (2014). Double stigmatization influence in oncogeriatry. Psycho-oncology.

Kenis, C., Heeren, P., Bron, D., Decoster, L., Moor, R., Pepersack, T., Langenaeken, C., Rasschaert, M., Jerusalem, G., Van Rijswijk, R., Lobelle, J.-P., Flamaing, J., Milisen, K., & Wildiers, H. (01 October 2014). Multicenter implementation of geriatric assessment in Belgian patients with cancer: A survey on treating physicians' general experiences and expectations. Journal of Geriatric Oncology, 5 (4), 431-438. doi:10.1016/j.jgo.2014.06.043

Paye, A., Truong, A., Yip, C., Cimino, J., Blacher, S., Munaut, C., Cataldo, D., Foidart, J.-M., Maquoi, E., COLLIGNON, J., Delvenne, P., Jerusalem, G., Noël, A.* , & Sounni, N. E.*. (October 2014). EGFR activation and signaling in cancer cells are enhanced by the membrane-bound metalloprotease MT4-MMP. Cancer Research, 74 (23), 6758-70. doi:10.1158/0008-5472.CAN-13-2994

Schroyen, S., Adam, S., JERUSALEM, G., & Missotten, P. (15 May 2014). Etude longitudinale en oncogériatrie: impact de la double stigmatisation. Poster session presented at Congrès International francophone de Gérontologie et Gériatrie, Liège, Belgium.

JERUSALEM, G. (22 February 2014). New chemotherapy drugs in metastatic breast cancer. Paper presented at Innovation in breast cancer - IBC 2014, Madrid, Spain.

Andre, F., Neven, P., Marinsek, N., Zhang, J., Baladi, J.-F., Degun, R., Benelli, G., Saletan, S., & Jerusalem, G. (2014). Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Current Medical Research and Opinion. doi:10.1185/03007995.2014.887002

BARTHELEMY, N., LENNERTS, E., MEYNS, M., DUYSINX, B., PAULUS, A., COMPERE, C., BOSQUEE, L., JERUSALEM, G., & COUCKE, P. (2014). LE DÉFI DU CONTRÔLE LOCAL DANS LE CANCER PULMONAIRE NON A PETITES CELLULES, LOCALEMENT AVANCE, NON OPERABLE. Revue Médicale de Liège, 69 (Supp 1), 75-80.

Coleman, R., Aksnes, A.-K., Naume, B., Garcia, C., Jerusalem, G., Piccart, M., Vobecky, N., Thuresson, M., & Flamen, P. (2014). A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Research and Treatment. doi:10.1007/s10549-014-2939-1

Duray, A., Demoulin, S., Petermans, J., Moutschen, M., Saussez, S., Jerusalem, G., & Delvenne, P. (2014). Vieillissement et cancer: coincidence ou relation etiologique? Revue Médicale de Liège, 69 (5-6), 276-81.

Jerusalem, G., RORIVE, A., & COLLIGNON, J. (2014). Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. Breast Cancer, 6, 43-57. doi:10.2147/BCTT.S38679

Leo, A. D., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., Pendergrass, K., Malorni, L., Garnett, S., Rukazenkov, Y., & Martin, M. (2014). Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. Journal of the National Cancer Institute, 106 (1), 337. doi:10.1093/jnci/djt337

Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., DeCara, J. M., Edvardsen, T., Flamm, S. D., Force, T., Griffin, B. P., & Lancellotti, P. (2014). Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography, 27 (9), 911-39. doi:10.1016/j.echo.2014.07.012

Wenric, S., Freres, P., Josse, C., Bours, V., & Jerusalem, G. (09 December 2013). A miRNA expression based diagnostic tool for breast cancer using random forests. Poster session presented at Benelux Bioinformatics Conference 2013.

JERUSALEM, G., ANDRE, F., CHEN, D., ROBINSON, D., OZGUROGLU, M., LANG, I., WHITE, M., TOI, M., TARAN, T., & GIANNI, L. (September 2013). Evaluation of Everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway : exploratory biomarker observations from the BOLERO-3 trial. European Journal of Cancer, 49 (Supplement 3), 8.

Wenric, S., JOSSE, C., Fasquelle, C., Poulet, C., Sticca, T., Boukerroucha, M., JERUSALEM, G., & Bours, V. (15 March 2013). Exome sequencing of tumors: relevance in copy-number alteration (CNA) analysis and fixed tissue samples. Poster session presented at 13th Annual Meeting of the Belgian Society of Human Genetics, Bruxelles, Belgium.

Ejlertsen, B., JERUSALEM, G., Hurvitz, S., de Boer, R., Taran, T., Sahmoud, T., & Burris, H. (March 2013). Everolimus Plus Exemestane Versus Everolimus or Capecitabine Monotherapy in Breast Cancer : BOLERO-6. Poster session presented at St. Gallen International Breast Cancer Conference, St Gallen, Switzerland.

Awada, A., Garcia, A. A., Chan, S., JERUSALEM, G., Coleman, R. E., Huizing, M. T., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Barrett-Lee, P. J., Cocquyt, V., Sideras, K., Young, D. E., Zhao, C., Chia, Y. L., Hoch, U., Hannah, A. L., & Perez, E. A. (2013). Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncology, 14 (12), 1216-1225. doi:10.1016/S1470-2045(13)70429-7

Benoit, A., Jerusalem, G., & GENNIGENS, C. (2013). Le cas clinique du mois. Métastase musculaire en présence d'un cancer de l'ovaire. Revue Médicale de Liège, 68 (11), 557-61.

Beyaert, R., Beaugerie, L., Van Assche, G., Brochez, L., Renauld, J.-C., Viguier, M., Cocquyt, V., JERUSALEM, G., Machiels, J.-P., Prenen, H., Masson, P., Louis, E., & De Keyser, F. (2013). Cancer risk in immune-mediated inflammatory diseases (IMID). Molecular Cancer, 12 (1), 98. doi:10.1186/1476-4598-12-98

COLLIGNON, J., & JERUSALEM, G. (2012). Les traitements cibles remplaceront-ils la chimiotherapie? Revue Médicale de Liège, 67 Spec No, 29-36.

GENNIGENS, C., & JERUSALEM, G. (2012). Pazopanib (Votrient) dans le traitement du cancer du rein et des sarcomes des tissus mous. Revue Médicale de Liège, 67 (7-8), 437-42.

ANDRE, C., COLLIGNON, J., RORIVE, A., MARTIN, M., MAWEJA, S., LIFRANGE, E., COUCKE, P., & JERUSALEM, G. (2011). Le cancer du sein chez la femme jeune. Revue Médicale de Liège, 66 (5-6), 397-399.

COUCKE, P., JANSEN, N., JANVARY, Z. L., LOUIS, C., VANDERICK, J., RORIVE, A., COLLIGNON, J., LIFRANGE, E., MAWEJA, S., & JERUSALEM, G. (2011). Accelerated partial breast irradiation: state of the art. Belgian Journal of Medical Oncology, 5 (1), 3-7.

GENNIGENS, C., & Jerusalem, G. (2011). Trabectedine (ET-743/Yondelis) dans le traitement des sarcomes des tissus mous et du cancer de l'ovaire. Revue Médicale de Liège, 66 (7-8), 452-5.

JERUSALEM, G., & COUCKE, P. (2011). Apport de la consultation oncologique multidisciplinaire dans le choix des options thérapeutiques. Revue Médicale de Liège, 66 (5-6), 311-314.

JERUSALEM, G., & SCHEEN, A. (2011). Editorial. Le cancer du sein. Revue Médicale de Liège, 66 (5-6), 225-228.

Withofs, N., Grayet, B., Tancredi, T., Rorive, A., Mella, C., Giacomelli, F., Mievis, F., Aerts, J., Waltregny, D., Jerusalem, G., & Hustinx, R. (2011). 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nuclear Medicine Communications, 32 (3), 168-176. doi:10.1097/MNM.0b013e3283412ef5

Freres, P., Collignon, J., Gennigens, C., Scagnol, I., Rorive, A., Barbeaux, A., Coucke, P., & Jerusalem, G. (March 2010). Le cancer du sein "triple négatif". Revue Médicale de Liège, 65 (3), 120-126.

Coucke, P., Vavassis, P., Vanderick, J., & Jerusalem, G. (07 January 2010). Het belang van de tumormarge na conservatieve chirurgie bij borstkanker in een vroeg stadium. Nederlandsch Tijdschrift voor Verloskunde en Gynaecologie, 6, 227-235.

Coucke, P., Jansen, N., Collignon, J., Janvary, Z. L., Rorive, A., Vanderick, J., & Jerusalem, G. (January 2010). Pourquoi les traitements de radiothérapie adjuvante pour cancer du sein ne comptent-ils plus autant de séances ? Revue Médicale de Liège, 65 (1), 10-14.

Collignon, J., Gennigens, C., Rorive, A., Coucke, P., Lifrange, E., Maweja, S., Fillet, G., & Jerusalem, G. (May 2009). ANTICORPS MONOCLONAUX ET CANCER DU SEIN: Actualités thérapeutiques. Revue Médicale de Liège, 64 (5-6), 279-83.

Coucke, P., Vavassis, P., Vanderick, J., & Jerusalem, G. (2009). Tumor Margin after conservative breast cancer surgery for early disease: an issue or not ? Belgian Journal of Medical Oncology, 3 (3), 93-100.

Gennigens, C., Collignon, J., Jerusalem, G., Rorive, A., & Sautois, B. (2009). Anticorps monoclonaux a usage therapeutique en hemato-oncologie. Generalites. Revue Médicale de Liège, 64 (5-6), 264-7.

GONNE, E., Collignon, J., Kurth, W., Thiry, A., Henry, F., Jerusalem, G., & Gennigens, C. (2009). Angiosarcome sur lymphoedeme chronique: un cas de syndrome de Stewart-Treves. Revue Médicale de Liège, 64 (7-8), 409-13.

Mievis, C., Jansen, N., Schleich, F., Gennigens, C., Rorive, A., Jerusalem, G., Fillet, G., & Sautois, B. (2009). Le cas clinique du mois. Reaction de rappel d'irradiation induite par l'administration de cyclophosphamide. Revue Médicale de Liège, 64 (4), 179-81.

Coucke, P., Barthelemy, N., Jansen, N., Trivière, N., & Jerusalem, G. (February 2008). Carcinome intracanalaire (in situ) du sein : pouvons-nous raisonnablement éviter la radiothérapie pour certaines patientes opérées ? Revue Médicale de Liège, 63 (2), 75-81.

Coucke, P., Barthelemy, N., Jansen, N. (Other coll.), Triviere, N. (Other coll.), & Jerusalem, G. (Other coll.). (2008). Carcinome intracanalaire (in situ) du sein : pouvons-nous raisonnablement éviter les radiothérapie pour certaines patientes opérées? Revue Médicale de Liège, 63 (2), 75-81.

Gennigens, C., Sautois, B., Rorive, A., Fillet, G., & Jerusalem, G. (2007). Actualites therapeutiques en oncologie: l'essor des therapeutiques ciblees. Revue Médicale de Liège, 62 (5-6, May-Jun), 391-8.

Jerusalem, G., Rorive, A., Gennigens, C., Sautois, B., Mievis, C., & Fillet, G. (2007). Actualités thérapeutiques en oncologie sénologique: place actuelle et perspectives des traitements cibles. Revue Médicale de Liège, 62 Spec No, 2-5.

Polus, M., Piront, P., Jerusalem, G., Sautois, B., Defechereux, T., de Leval, L., & Fillet, G. (February 2004). L'image du mois. Tumeur de Merkel : reponse majeure a la chimiotherapie. "Il n'y a pas que la neige qui fond au soleil". Revue Médicale de Liège, 59 (2), 67-8.

Gillain, S., Gennigens, C., Sautois, B., Polus, M., Bonnet, C., Fillet, G., & Jerusalem, G. (2004). Traitement du cancer du sein chez la personne âgée. Revue Médicale Suisse, 62, 1618-21.

Polus, M., Piront, P., Jerusalem, G., Sautois, B., Louis, E., Detroz, B., Laurent, S., Belaiche, J., & Fillet, G. (April 2003). Prevention primaire et secondaire du cancer colorectal. Revue Médicale de Liège, 58 (4), 247-53.

Pelerin, D., Silvestre, R. M., Jerusalem, G., Sautois, B., Polus, M., & Fillet, G. (December 2002). Comment je traite ... par hormonotherapie des patientes developpant des complications thrombo-emboliques lors du traitement d'un cancer du sein par tamoxifene. Revue Médicale de Liège, 57 (12), 755-6.

Polus, M., Honore, P., De Roover, A., Detry, O., Detroz, B., Jerusalem, G., Sautois, B., & Fillet, G. (December 2002). La carcinomatose hepatique du cancer colorectal: actualites therapeutiques. Revue Médicale de Liège, 57 (12), 771-8.

Polus, M., Bours, V., Jerusalem, G., Sautois, B., & Fillet, G. (July 2002). Comment je traite.... Le cancer avance du pancreas par une approche innovante dirigee contre les nouvelles cibles. Revue Médicale de Liège, 57 (7), 428-32.

Polus, M., Jerusalem, G., Sautois, B., Silvestre, R. M., & Fillet, G. (March 2002). Comment je traite.... Un cancer du pancreas avance. Revue Médicale de Liège, 57 (3), 131-4.

Polus, M., Jerusalem, G., Sautois, B., Silvestre, R. M., Collette, M. Y., Closon, M. T., & Fillet, G. (February 2002). Etude clinique du mois. Radio-chimiotherapie et chimiotherapie adjuvante apres resection a visee curative du cancer du pancreas: resultats de l'etude randomisee ESPAC-1. Revue Médicale de Liège, 57 (2), 119-22.

Warland, V., Jerusalem, G., Hustinx, R., Beguin, Y., Silvestre, R. M., Fassotte, M.-F., Foidart, J., & Fillet, G. (2002). Comment etablir le bilan de fin de traitement des patients atteints de lymphomes non-hodgkiniens (LNH) de malignite intermediaire ou elevee? Revue Médicale de Liège, 57 (12), 779-84.

Sylvestre, R.-M., Jerusalem, G., Sautois, B., Beguin, Y., & Fillet, G. (2001). Nouvelles approches thérapeutiques puor l'hypernéphrome métastasique. Médecine et Hygiène, 59, 1607-1609.

JERUSALEM, G., & BEGUIN, Y. (June 2000). Commentary on "Positron emission tomography in lymphoma : comparison with computed tomography and Gallium-67 single photon emission computed tomography imaging". Clinical Lymphoma, 1 (1), 75-76.

Bonnet, C., Jerusalem, G., Bours, V., & Fillet, G. (2000). Approches thérapeutiques du cancer ovarien. Médecine et Hygiène, 58, 1625-1628.

Jerusalem, G., Bours, V., & Fillet, G. (1999). Actualités thérapeutiques dans le traitement du cancer colorectal. Médecine et Hygiène, 57, 1552-1554.

Jerusalem, G., Warland, V., Najjar, F., Paulus, P., Fassotte, M. F., Fillet, G., & Rigo, P. (January 1999). Whole-Body 18f-Fdg Pet for the Evaluation of Patients with Hodgkin's Disease and Non-Hodgkin's Lymphoma. Nuclear Medicine Communications, 20 (1), 13-20. doi:DOI:10.1080/00006231-199901000-00004

Najjar, F., Jerusalem, G., Paulus, P., Fillet, G., & Rigo, P. (1999). Intérêt clinique de la tomographie à émission de positons dans la détection et le bilan d'extension des lymphomes non Hodgkiniens de malignité intermédiaire ou élevée. Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 23, 281-290.

Pierard, G., Nikkels, N., Nikkels, A., Arrese Estrada, J., Pierard, C., Jerusalem, G., Beguin, Y., & Fillet, G. (1998). Epidermal Calprotectin Expression in Lymphocyte-Depleted Cutaneous Graft-versus-Host Reaction. Archivos Argentinos de Dermatologia, 48, 139-142.

Jerusalem, G., & Fillet, G. (1997). Les taxanes : un nouvelle classe d'agents cytotoxiques. Médecine et Hygiène, 55, 1501-1504.

Rigo, P., Paulus, P., Kaschten, B., Hustinx, R., Bury, T., Jerusalem, G., Benoit, T., & Foidart-Willems, J. (December 1996). Oncological Applications of Positron Emission Tomography with Fluorine-18 Fluorodeoxyglucose. European Journal of Nuclear Medicine, 23 (12), 1641-74. doi:10.1007/BF01249629

Jerusalem, G., Detroz, B., Herman, P., Dohogne, A., Closon, M. T., Jacquet, N., Honoré, P., Bruyninx, L., Fillet, G., Fassotte, M.-F., Bours, V., & Lipcsei, G. (1995). Approche thérapeutique du cancer épithélial de l'ovaire au CHU Sart Tilman : Conclusions de la réunion interdisciplinaire du 22 mars 1995. Revue Médicale de Liège, 50, 469-471.

Rigo, P., Paulus, P., JERUSALEM, G., BURY, T., Deneufbourg, J.-M., Depas, G., Benoît, T., Larock, M.-P., & Foidart, J. (1995). Indications cliniques de la tomographie à positons au 18FDG en oncologie. Expérience préliminaire et revue de la littérature. Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 19, 73-89.